India, Sept. 17 -- The Union Health Ministry has issued an advisory dated September 16, 2026, to States and Union Territories that have adopted the Clinical Establishments (Registration and Regulation) Act, 2010, reiterating the regulatory framework governing stem cell research and therapy.
The advisory follows a January 30, 2026 Supreme Court judgment and states that stem cell therapy may be offered as standard clinical care only for disease conditions or indications approved by the Ministry of Health & Family Welfare.
For Autism Spectrum Disorder (ASD), the therapeutic use of any type of stem cell is to remain restricted to duly approved clinical trials, in line with the National Guidelines for Stem Cell Research, 2017, issued by ICMR a...